Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.
Muhammet GülhanUğur ÖnalNeşe DemirciGulcan CetinAbdullah CalisirDamla KöksalanKübra SolmazAyhan KarsÇetin KılınçSedat GultenPublished in: Revista da Associacao Medica Brasileira (1992) (2022)
The results showed that tocilizumab is an effective treatment option for coronavirus disease 2019 disease and reduces mortality, but the key point is timing.
Keyphrases
- coronavirus disease
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- respiratory syndrome coronavirus
- cardiovascular events
- risk factors
- cardiovascular disease
- coronary artery disease
- patient reported outcomes